MLEC (MLEC) Stock Price & Analysis
MLEC (MLEC) rose 0.00% to USD 6.93 as of September 8, 2026 at 21:27 UTC, according to Nexqual real-time market data.
MLEC last closed at USD 6.93; the session ranged USD 6.61–7.1 on volume of 49,623 shares. Market capitalization is $5.03M, with a 52-week range of USD 3.08–23.22 (NCM). Source: Nexqual, September 8, 2026 at 21:27 UTC.
Key Statistics (as of September 8, 2026 at 21:27 UTC)
| Price | USD 6.93 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 6.93 |
| Open | USD 6.84 |
| Day Range | USD 6.61 – 7.1 |
| 52-Week Range | USD 3.08 – 23.22 |
| Volume | 49,623 shares |
| Market Cap | $5.03M |
| Exchange | NCM |
Technical Analysis (MLEC)
Nexqual's technical model rates MLEC "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 21:27 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.78 (neutral) |
| vs SMA50 | Below (USD 7.22) |
| MACD | -0.09 (negative) |
Analyst Ratings (MLEC)
Wall Street analysts rate MLEC "None", per Nexqual as of September 8, 2026 at 21:27 UTC.
| Consensus Rating | None |
|---|
Earnings (MLEC)
Source: Nexqual, September 8, 2026 at 21:27 UTC.
Financials & Fundamentals (MLEC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, September 8, 2026 at 21:27 UTC.
Financial Health Score (MLEC)
Nexqual rates MLEC's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 21:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (MLEC)
| Insider Ownership | +21.06% |
|---|---|
| Institutional Ownership | +0.07% |
| Shares Outstanding | 726,118 |
| Short % of Float | +0.51% |
Source: Nexqual, September 8, 2026 at 21:27 UTC.
Leadership (MLEC)
MLEC is led by Alejandro Antalich (age 51), Chief Executive Officer, per Nexqual as of September 8, 2026 at 21:27 UTC.
| Chief Executive Officer | Alejandro Antalich (age 51) |
|---|---|
| Co-Founder & Chief Product Officer | Henk Hoogenkamp (age 37) |
| Chief Financial Officer | Valeria Falottico (age 43) |
| Chief Technology Officer | Paola Díaz Dellavalle (age 49) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals plc | USD 0.83 | ▲ 4.14% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.96 | ▲ 7.1% |
| CMND | Clearmind Medicine Inc. | USD 1.03 | ▼ 39.41% |
| ATPC | Agape ATP Corporation | USD 2.31 | ▼ 3.35% |
| ARBB | ARB IOT Group Limited | USD 4.42 | ▲ 4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 21:27 UTC. This page is informational and not investment advice.